Superworth

Stoke Therapeutics profit margin STOK

Gross, operating and net profit as a share of revenue over the last twelve months, from 2025.

Net margin, 12 months
n/m
not a meaningful number
Peer median
13.3%

Stoke Therapeutics' net margin works out at −754% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025−3.7%−11.2%
FY2024n/an/a
FY2023n/an/a
FY2022n/an/a
FY2021n/an/a
FY2020n/an/a
FY2019n/an/a
FY2018n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26n/an/an/a
Q1 FY26n/an/an/a
Q4 FY25−3.7%n/a−11.2%
Q3 FY2519.7%n/a13.2%
Q2 FY2526.3%n/a20.2%
Q1 FY2526.3%n/a20.0%
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY23n/an/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Stoke Therapeutics' size, closest first, today.

CompanyProfit margin
STOKStoke Therapeuticsn/m
PAHCPhibro Animal Health6.6%
ANIPANI Pharmaceuticals11.1%
ANABAnaptysbion/m
PCRXPacira BioSciences2.0%
HRMYHarmony Biosciences18.9%
OMEROmerosn/m
PBHPrestige Consumer Healthcare15.6%
AMPHAmphastar Pharmaceuticals10.8%
NRIXNurix Therapeutics42.0%
ABUSArbutus Biopharma84.2%
Peer median13.3%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Stoke Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.